148 related articles for article (PubMed ID: 15957243)
21. Interleukin-10 in non-Hodgkin's lymphoma.
Cortes J; Kurzrock R
Leuk Lymphoma; 1997 Jul; 26(3-4):251-9. PubMed ID: 9322887
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic and prognostic value of interleukin-6 in malignant non-Hodgkin's lymphomas].
Serebriakov NB; Novik AA; Shamanskiĭ SV; Krivolapov IuA; Voloshin SV; D'iakova VV; Snetkova IG; Katkova IV; Zhiburt EB
Vestn Ross Akad Med Nauk; 1998; (10):32-6. PubMed ID: 9846110
[TBL] [Abstract][Full Text] [Related]
26. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
29. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
30. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
31. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
32. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Bohlen H; Kessler M; Sextro M; Diehl V; Tesch H
Ann Hematol; 2000 Mar; 79(3):110-3. PubMed ID: 10803931
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.
Bogunia-Kubik K; Mazur G; Wróbel T; Kuliczkowski K; Lange A
Tissue Antigens; 2008 Feb; 71(2):146-50. PubMed ID: 18201362
[TBL] [Abstract][Full Text] [Related]
34. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
35. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
36. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
37. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
Voorzanger N; Touitou R; Garcia E; Delecluse HJ; Rousset F; Joab I; Favrot MC; Blay JY
Cancer Res; 1996 Dec; 56(23):5499-505. PubMed ID: 8968107
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
[TBL] [Abstract][Full Text] [Related]
39. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome.
Pamuk GE; Turgut B; Demir M; Vural O
J Exp Clin Cancer Res; 2006 Dec; 25(4):537-41. PubMed ID: 17310845
[TBL] [Abstract][Full Text] [Related]
40. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]